Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,774.00
Bid: 1,774.00
Ask: 1,774.50
Change: 13.00 (0.74%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,776.00
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London open: Markets rise as earnings impress

Wed, 24th Jul 2013 08:53

Well-received updates and results from easyJet, ARM Holdings, Tate & Lyle, Compass and Kingfisher pushed the FTSE 100 firmly into positive territory on Wednesday morning, as markets shrugged off disappointing economic data from China.HSBC's flash China manufacturing purchasing managers' index (PMI) fell from 48.2 to 47.7 in July, missing expectations of no change. Any figure below 50 indicates a contraction in activity in the sector."Under normal circumstances, this would weigh heavily on investor sentiment and therefore risk assets, such as the European indices, however that is not the case this morning," said Market Analyst Craig Erlam from Alpari.Downside risks to growth were tempered yesterday by the country's Premier Li Keqiang who assured that the pace of expansion would not fall below the "bottom line" of 7.0% this year, indicating that any slowdown would be met with more stimulus."This should limit the short-term negativity surrounding poor Chinese data because it seems for now that growth is guaranteed to remain at these higher levels," Erlam said.FTSE 100: Updates impress early oneasyJet surged this morning after the budget airline achieved a 10.5% rise in third-quarter revenue to £1.14bn, bolstered by an increase in capacity and growth in revenue per seat. Chip designer ARM Holdings was also on the riser after delivering better-than-expected second-quarter sales and profits. The company also said that dollar revenues would be "at least in line" with market expectations.Food ingredients firm Tate & Lyle gained after saying that adjusted profits were in line with expectations in spite of tough weather conditions in the States in the first quarter.Foodservice and support services company Compass rose after saying expectations for the full year remain "positive and unchanged" following a strong third quarter.Kingfisher, the DIY retail group behind B&Q and Screwfix, said it is on track to hit expectations for the first half after a pick-up in activity in the second quarter. Pharmaceuticals giant GlaxoSmithKline was trading higher early on ahead of its results out later on today.Exchange operator London Stock Exchange was in the red after going ex-dividend. Standard Chartered was also lower after Morgan Stanley downgraded the stock to 'equal weight' and cut its target price from 1,830p to 1,627p.FTSE 100 - RiserseasyJet (EZJ) 1,408.00p +5.39%ARM Holdings (ARM) 923.50p +2.84%International Consolidated Airlines Group SA (CDI) (IAG) 292.30p +2.24%Tate & Lyle (TATE) 839.00p +1.88%Antofagasta (ANTO) 871.00p +1.63%Compass Group (CPG) 888.50p +1.43%Associated British Foods (ABF) 1,888.00p +1.40%Kingfisher (KGF) 390.20p +1.40%GlaxoSmithKline (GSK) 1,694.00p +1.29%Royal Dutch Shell 'B' (RDSB) 2,333.00p +1.28%FTSE 100 - FallersMeggitt (MGGT) 537.00p -1.83%Croda International (CRDA) 2,405.00p -1.80%Standard Chartered (STAN) 1,496.50p -1.25%Amec (AMEC) 1,059.00p -1.21%Rolls-Royce Holdings (RR.) 1,169.00p -0.93%Randgold Resources Ltd. (RRS) 4,802.00p -0.89%BG Group (BG.) 1,203.00p -0.62%Sage Group (SGE) 356.80p -0.61%RSA Insurance Group (RSA) 126.40p -0.47%London Stock Exchange Group (LSE) 1,548.00p -0.45%FTSE 250 - RisersWetherspoon (J.D.) (JDW) 704.50p +5.46%Imagination Technologies Group (IMG) 262.50p +4.71%Bumi (BUMI) 224.90p +3.88%Hochschild Mining (HOC) 168.90p +2.99%Mitchells & Butlers (MAB) 424.70p +2.34%Dialight (DIA) 1,212.00p +2.28%Oxford Instruments (OXIG) 1,377.00p +2.23%Evraz (EVR) 107.50p +1.99%Kazakhmys (KAZ) 277.30p +1.76%Thomas Cook Group (TCG) 150.80p +1.55%FTSE 250 - FallersRenishaw (RSW) 1,469.00p -6.25%TalkTalk Telecom Group (TALK) 243.90p -3.21%Chemring Group (CHG) 301.50p -1.50%African Barrick Gold (ABG) 115.10p -1.46%Carpetright (CPR) 668.00p -1.33%Ocado Group (OCDO) 320.90p -1.26%ITE Group (ITE) 289.80p -1.09%Home Retail Group (HOME) 153.90p -1.03%F&C Commercial Property Trust Ltd. (FCPT) 109.70p -0.99%Beazley (BEZ) 223.50p -0.97%BC
More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.